FDA Faces Fresh Drug-Device Headaches After DC Circ. Loss

A new D.C. Circuit ruling will make it harder for the U.S. Food and Drug Administration to treat products as drugs when they fit into overlapping definitions of drugs and medical...

Already a subscriber? Click here to view full article